Investment Research & Advisory Group Inc. Has $1.12 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Investment Research & Advisory Group Inc. lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 24.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,763 shares of the medical research company’s stock after selling 897 shares during the period. Investment Research & Advisory Group Inc.’s holdings in Thermo Fisher Scientific were worth $1,120,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Nuveen LLC bought a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at approximately $532,360,000. Sarasin & Partners LLP acquired a new stake in Thermo Fisher Scientific in the first quarter valued at approximately $242,991,000. EdgePoint Investment Group Inc. acquired a new position in shares of Thermo Fisher Scientific during the 1st quarter worth $172,139,000. Cohen Investment Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 6,655.5% in the 1st quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company’s stock valued at $167,271,000 after purchasing an additional 331,180 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Thermo Fisher Scientific by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock worth $1,368,859,000 after buying an additional 329,974 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock valued at $14,182,963 in the last 90 days. 0.33% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on TMO. William Blair started coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They set an “outperform” rating for the company. Evercore ISI lowered their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating on the stock in a report on Tuesday, July 8th. HSBC restated a “hold” rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Sunday, September 7th. Finally, Hsbc Global Res cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $588.35.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $464.18 on Monday. The firm’s 50-day moving average is $476.70 and its 200-day moving average is $447.15. The company has a market cap of $175.28 billion, a price-to-earnings ratio of 26.85, a PEG ratio of 2.52 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $623.77.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period last year, the business earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.